Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria.[L11830] It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps in the biosynthesis of nucleic acids and proteins which are necessary for bacterial growth and division, and using them in conjunction helps to slow the development of bacterial resistance.[L11830] In this combination, sulfamethoxazole is useful for the treatment of a variety of bacterial infections, including those of the urinary, respiratory, and gastrointestinal tracts.
Sulfamethoxazole and Trimethoprim (Double Strength)
Bactrim DS Roche Tab
Sulfamethoxazole and Trimethoprim Double Strength
Sulfatrim Pediatric
Bactrim DS
SULFAMETHOXAZOLE and TRIMETHOPRIM
SULFAMETHOXAZOLE AND TRIMETHOPRIM double strength
Riva-sep DS
Septra Injection
Teva-trimel
Sulfamethoxazole and Trimethoprim Tablets
Protrin Df Tab
Roubac Tab 160/800
Septra Pediatric Suspension
Roubac Tab 80/400
Sulfatrim DS
Bactrim Roche Tab
Teva-trimel DS
Bactrim
Apo-sulfatrim Oral Suspension
Trisulfa DS Tab
Bactrim Roche Inj
Apo Sulfamethoxazole Tab 500mg
Septra DS Tablets
Sulfamethoxazole Tab 500mg
Sulfatrim
Bactrim Roche Suspension Paediatric
Sulfamethox-TMP DS
Sulfamethoxazole and Trimethoprim for Injection, USP
Nu-cotrimox Sus 40/8mg/ml
Trisulfa Tab
Nu-cotrimox-DS Tab 800/160mg
Septra DS
Sulfamethoxazole and Trimethoprim DS
Sulfamethoxazole
Septra Grape
Septra
Trisulfa S Suspension
sulfamethoxazole-trimethoprim (SMZ)
Sulfamethoxazole and Trimethoprim
Indication
Sulfamethoxazole is indicated in combination with trimethoprim, in various formulations, for the following infections caused by bacteria with documented susceptibility: urinary tract infections, acute otitis media in pediatric patients (when clinically indicated), acute exacerbations of chronic bronchitis in adults, enteritis caused by susceptible _Shigella_, prophylaxis and treatment of _Pneumocystis jiroveci_ pneumonia, and travelers' diarrhea caused by enterotoxigenic _E. coli_.[L11830,L11863] In Canada, additional indications include the adjunctive treatment of cholera, treatment of bacillary dysentery, nocardiosis, and second-line treatment of brucellosis in combination with [gentamicin] or [rifampicin].[L11851]
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682